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Abstract
Background: To get insight into molecular mechanisms underlying insulin resistance, we compared acute in vivo
effects of insulin on adipose tissue transcriptional profiles between obese insulin-resistant and lean insulin-sensitive
women.
Methods: Subcutaneous adipose tissue biopsies were obtained before and after 3 and 6 hours of intravenously
maintained euglycemic hyperinsulinemia from 9 insulin-resistant and 11 insulin-sensitive females. Gene expression
was measured using Affymetrix HG U133 Plus 2 microarrays and qRT-PCR. Microarray data and pathway analyses
were performed with Chipster v1.4.2 and by using in-house developed nonparametric pathway analysis software.
Results: The most prominent difference in gene expression of the insulin-resistant group during hyperinsulinemia
was reduced transcription of nuclear genes involved in mitochondrial respiration (mitochondrial respiratory chain,
GO:0001934). Inflammatory pathways with complement components (inflammatory response, GO:0006954) and
cytokines (chemotaxis, GO:0042330) were strongly up-regulated in insulin-resistant as compared to insulin-sensitive
subjects both before and during hyperinsulinemia. Furthermore, differences were observed in genes contributing
to fatty acid, cholesterol and triglyceride metabolism (FATP2, ELOVL6, PNPLA3, SREBF1) and in genes involved in
regulating lipolysis (ANGPTL4) between the insulin-resistant and -sensitive subjects especially during
hyperinsulinemia.
Conclusions: The major finding of this study was lower expression of mitochondrial respiratory pathway and
defective induction of lipid metabolism pathways by insulin in insulin-resistant subjects. Moreover, the study
reveals several novel genes whose aberrant regulation is associated with the obese insulin-resistant phenotype.
Background
Instead of merely being a storage depot, adipose tissue is
now recognized as an important regulator of energy
homeostasis and a central player in the development of
insulin resistance [1,2]. The development of insulin
resistance is closely associated with obesity [2]. How-
ever, it is not known why all obese subjects are not
insulin-resistant and insulin resistance can also be
observed in lean subjects, highlighting the fact that the
molecular mechanisms underlying insulin resistance are
still largely unknown.
A number of transcriptome studies have reported dif-
ferences in adipose tissue mRNA expression at fasting
state between obese and lean subjects (reviewed in [3]).
Most of these investigations have been performed after
an overnight fast [4-14] and they compare differences
between obese and non-obese subjects [5,6,10-14], pre-
dominantly in males or mixed groups consisting of both
males and females.
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including global transcriptome analyses, have implicated
low-grade adipose tissue inflammation as one of the
central factors involved in the development of insulin
resistance [15]. As an example, analysis of subcutaneous
adipose tissue transcript profiles in monozygotic twins
revealed elevated expression of several pro-inflammatory
cytokines and complement components in the in the
obese, insulin-resistant co-twins as compared to the
non-obese ones [12].
Using human whole genome microarrays, Dahlman
et al. [16] observed down-regulation of mitochondrial
electron transport chain genes in both visceral and sub-
cutaneous adipose tissue of type 2 diabetic subjects dur-
ing fasting. A study on monozygotic twins discordant
for BMI reported decreased branched-chain amino acid
catabolism and reduced mitochondrial DNA copy num-
ber in the adipose tissue of obese co-twins, further
emphasizing a role for mitochondrial energy and amino
acid metabolism in obesity and insulin resistance [12].
Baranova et al. [4] reported mRNA expression patterns
in visceral adipose tissue of morbidly obese patients com-
pared with non-obese controls. The differentially
expressed genes included those related to lipid and glucose
metabolism, membrane transport, and promotion of the
cell cycle. Using isolated adipocytes, Yang et al. [14] dis-
covered through comparison of gene expression between
non-diabetic insulin-resistant first degree relatives of T2D
patients and healthy controls, that insulin resistance is
associated with impaired adipogenesis.
While previous studies have identified a number of fac-
tors involved in adipogenesis, adipose tissue lipid and
energy metabolism, as well as in inflammatory processes
to be abnormally expressed, the alterations could be
unrelated to insulin action and merely reflect the impact
of factors other than insulin on gene expression in obese
as compared to non-obese subjects. To relate the
abnormalities to impaired insulin response, comparison
of differences in acute regulation of the transcriptome by
insulin between obese and non-obese subjects would
seem of interest. To our knowledge there are no such
data available. Therefore the present study was underta-
ken to compare transcriptional differences in subcuta-
neous adipose tissue derived from obese insulin-resistant




T h en a t u r ea n dp o t e n t i a lr i s k so ft h es t u d yw e r e
explained to all subjects prior to obtaining their written
informed consent. The study was carried out in accor-
dance with the principles of the declaration of Helsinki.
The protocol was approved by the ethics committee of
the Helsinki University Central Hospital.
Study subjects
A total of 20 non-diabetic Caucasian women were
recruited based on the following inclusion criteria: 1) age
18-60 years; 2) no known acute or chronic disease other
than obesity based on history, physical examination and
standard laboratory tests (blood counts, serum creatinine,
thyroid stimulating hormone, electrolyte concentrations,
and electrocardiogram); and 3) body mass index (BMI) <
40 kg/m
2. Other exclusion criteria included pregnancy or
treatment with drugs that may alter glucose tolerance.
Data on expression of some individual genes from these
women have previously been published [17,18]. Whole
body insulin sensitivity was measured in each subject
using the euglycemic hyperinsulinemic clamp technique,
as described [19]. The duration of the insulin infusion
was 6 hours and insulin infusion rate 1 mU/kg·min.
Metabolic studies were performed after an overnight
fast. Two 18-gauge catheters (Venflon; Viggo-Spec-
tramed, Helsingborg, Sweden) were inserted, one in an
antecubital vein for infusion of insulin (Insulin Actrapid;
Novo Nordisk, Denmark) and glucose, and another ret-
rogradely in a heated hand vein to obtain arterialized
venous blood for measurement of glucose concentra-
tions every 5 min and serum free insulin concentration
every 30 min. The rate of the continuous insulin infu-
sion was 1 mU kg - 1 min - 1 for 6 h. Normoglycemia
was maintained by adjusting the rate of a 20% glucose
infusion based on plasma glucose measurements from
arterialized venous blood every 5 min. Wholebody insu-
lin sensitivity was determined from the glucose infusion
rate required to maintain normoglycemia between 30
and 360 min [19].
Other measurements
Blood samples were taken after an overnight fast for
measurement of plasma glucose, serum insulin, C-pep-
tide, serum triglyceride and total and HDL cholesterol
concentrations, as described [17].
Adipose tissue biopsies, total RNA preparation and
microarray processing
Needle aspiration biopsies of abdominal subcutaneous
fat were taken under local intracutaneous anesthesia at
baseline (0 h) and after 3 and 6 hours of hyperinsuline-
mia from the left and right lower abdominal region [20]
and frozen in liquid nitrogen until analysis. Total RNA
was prepared from frozen fat tissue (on the average 250
mg) using the RNeasy Lipid Tissue Mini Kit (Qiagen)
according to the manufacturer’s protocol. Quality of
RNA was analyzed using the 2100 Bioanalyzer platform
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analysis, the five most insulin-sensitive and the five
most insulin-resistant patients were selected based on
their whole body insulin sensitivity (M-value). Two
micrograms of total RNA from time point 0 h (fasting)
and 3 h (hyperinsulinemia) were processed according to
the conventional Affymetrix eukaryotic RNA labeling
protocols (Affymetrix, Santa Clara, CA). Hybridization,
staining and washing of the Affymetrix U133 Plus 2.0
chips were performed using the Affymetrix Fluidics Sta-
tion 450 and Hybridization Oven 640 under standard
conditions.
Pathway analysis
Analysis of the microarray expression data was done
using the R/Bioconductor through a graphical user
interface, Chipster (v1.4.3, CSC, Finland, http://chipster.
csc.fi/). The microarray data has been submitted to
GEO database (accession number, GSE26637). Pre-pro-
cessing of the expression data was performed using GC-
RMA algorithm and re-annotated probe set libraries by
the University of Michigan http://brainarray.mbni.med.
umich.edu. Expression data were filtered before pathway
analysis by flags. All probes with status ‘present’ or
‘marginal’ in at least 3 out of 5 chips in one of the four
condition groups (fasted insulin-sensitive, fasted insulin-
resistant, hyperinsulinemic insulin-sensitive, hyperinsuli-
nemic insulin-resistant) were accepted for analysis.
Probes passing these criteria were then divided into up
and down-regulated probes by their fold change in
expression. Analysis was done separately for fasting
samples (fasted insulin-resistant/fasted insulin sensitive
fold change) and for hyperinsulinemia samples (hyperin-
sulinemic insulin-resistant/hyperinsulinemic insulin-sen-
sitive fold change). Probe lists were ranked according to
statistical significance (Student’s t-test) and submitted to
the pathway analysis software. The top 10 up and down-
regulated pathways are reported. Similarly, we analyzed
which biological pathways show the strongest response
in gene expression after systemic stimulation by insulin.
Analyses were performed separately for the insulin-resis-
tant and the insulin-sensitive groups (hyperinsulinemic
insulin-sensitive/fasted insulin-sensitive fold change and
hyperinsulinemic insulin-resistant/fasted insulin-resistant
fold change). After defining the most insulin responsive
pathways, we selected two of them, and compared their
expression between the study groups during hyperinsuli-
nemia. Pathway analysis was performed using an in-
house developed non-parametric pathway analysis soft-
ware to resolve which gene sets from GO classification
are enriched in a list of genes as described recently [12].
As a feature of the dendrogram-like structure of the GO
classifications, gene sets get progressively larger and less
descriptive when moving down the tree. Therefore, in
order to concentrate on the biologically more meaning-
ful pathway collections, an arbitrary cut-off of a maxi-
mum of 150 genes per pathway was chosen as the
largest reported gene list. In addition, all pathways refer-
ring to cellular localization were removed.
List of differentially expressed genes
Expression data was filtered with stringent criteria to
reveal only the most significant differentially expressed
probes from the dataset. Every probe with flag status ‘pre-
sent’ was accepted and the data were further filtered by
standard deviation (95% filtered out). Statistical analysis
was performed with 2-way analysis of variance (ANOVA),
using R-statistics, and taking into account the repeated
measures from the same subjects (Additional file 1). All
probes with p < 0.05 after Benjamini-Hochberg multiple
testing correction [21] were accepted. Two supplement
tables were generated: one for significantly regulated
probes between the groups (insulin-resistant vs. insulin-
sensitive) and a second one for significantly regulated
probes by insulin treatment (fasting vs. hyperinsulinemia).
Quantitative RT-PCR
Quantitative RT-PCR (qPCR) was used to measure the
relative abundance of interesting transcripts found from
the microarray analysis. Samples from 20 women,
including the 10 samples used for the microarray analy-
s i s ,a tt h r e et i m ep o i n t s( 0h ,3ha n d6h )w e r ea n a -
lyzed. Reverse transcription was performed using M-
MLV reverse transcriptase (Invitrogen) using oligo(dT)
12-18 primers. Power SYBR
® Green PCR Master Mix
and ABI 7900 HT system (Applied biosystems) were
used for quantitative PCR analysis with gene specific
primers (Additional file 2: Table S1
Q1)a n d1n go ft e m -
plate in a final reaction volume of 10 μl. Genorm algo-
rithm [22] was used to validate three different control
genes for normalization. Data were normalized to geo-
metric mean of two control genes, beta actin (ACTB)
and large ribosomal protein 0 (RPLP0).
Statistical analyses
Clinical and biochemical characteristics in the insulin-
sensitive and the insulin-resistant groups were compared
using the Mann-Whitney U test and 2-way ANOVA.
The calculations were performed with SPSS statistics
18.0 for Windows (SPSS, Chicago, IL). All data are
shown as mean ± standard error of mean.
Results
Clinical characteristics of the study subjects
The clinical characteristics of the study subjects are
summarized in Table 1. The characteristics are reported
separately for subjects in the microarray study and for
the subjects in the qRT-PCR experiment. Markers of
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concentrations were higher, and HDL-cholesterol con-
centration lower in the insulin-resistant group. During
insulin infusion, serum insulin concentrations were
similar between the lean insulin-sensitive and the obese
insulin-resistant groups (68 ± 6 vs. 84 ± 10 mU/l,
respectively; NS). By definition, whole-body insulin sen-
sitivity was 131% higher in the insulin-sensitive than the
insulin-resistant group in the microarray experiment
(n = 10) (9.7 ± 0.5 vs. 4.2 ± 0.4 mg kg - 1 min - 1, p <
0.009) and 107% higher in the entire study group (n =
20) (8.7 ± 0.4 vs. 4.2 ± 0.4 mg kg 1 min 1, p < 0.0001).
Moreover, all indicators of obesity (body weight, BMI,
whole-body-fat, fat mass, and waist-to-hip ratio were
significantly higher in the insulin-resistant subjects than
in the sensitive ones.
Inflammatory pathways are up-regulated in the insulin-
resistant women
Activation of inflammatory pathways was a predominant
phenotype in the insulin-resistant group after overnight
fast (Table 2). The inflammatory gene expression pattern
consisted mainly of two aspects of the immune response:
genes involved in complement activation (inflammatory
response, GO:0006954, p = 2.0E-10) and those involved in
cellular chemotactic activity (taxis/chemotaxis,
GO:0006935, p = 1.8E-07). The inflammatory response
pathway included complement 1q subcomponent, B chain
(C1QB), A chain (C1QA)a n dCc h a i n( C1QC). In this
pathway, the gene most strongly elevated in the insulin-
resistant group was LDL-associated phospholipase A2
(PLA2G7 or LDL-PLA2) (Figure 1A).
The second aspect of the inflammatory phenotype
involved a number of chemokines and adhesion mole-
cules in the taxis/chemotaxis pathways. The most pro-
minently elevated genes in the insulin-resistant subjects
were the spleen tyrosine kinase (SYK), chemokine
CCL13,a n db e t a2i n t e g r i n( ITGB2)i n v o l v e di nl e u k o -
cyte adhesion (Figure 1B). Up-regulation of inflamma-
tory pathways similar to those in the fasted situation
was observed between the groups during hyperinsuline-
mia: The most divergent pathways here included inflam-
matory response (GO:0006954, p = 3.7E-07) and
regulation of immune system process (GO:0002682, p =
1.0E-06) (Table 3). Expression of marcrophage marker
CD36 was 14.2% increased in the insulin-resistant
group.
ANOVA analysis of single genes expressed differentially
between the groups revealed additional genes of interest
such as osteopontin (SPP1), matrix metalloproteinase 9
(MMP9), branched chain amino-acid transaminase 1
(BCAT1) and EGF-like protein 6 (EGFL6). These were
expressed at higher levels in the insulin-resistant than the
insulin-sensitive group (Additional file 3: Table S2).
Monocarboxylic acid metabolism is down-regulated in the
insulin-resistant women during fasting
Expression of genes involved in monocarboxylic acid meta-
bolism (GO:0032787, p = 5.6E-06), most of which repre-
sent the fatty acid metabolism pathway (GO:0006631, p =
5.8E-05), was reduced in the insulin-resistant group as
compared with the insulin-sensitive group after an over-
night fast (Table 4). Fatty acid transporter 2 (SLC27A2 or
FATP2) was the most differentially expressed gene in this
Table 1 Physical and biochemical characteristics of the study subjects divided into insulin-sensitive and -resistant
groups on the basis of their median whole-body insulin sensitivity
Microarray qPCR
Insulin Sensitive Insulin Resistant p value Insulin
Sensitive
Insulin Resistant pvalue
n5 5 - 1 1 9 -
Age (years) 33 ± 6 39 ± 5 NS 32 ± 4 39 ± 3 NS
Body weight (kg) 60 ± 4 90 ± 5 0.009 69 ± 4 90 ± 5 0.003
BMI (kg/m
2) 22.0 ± 0.7 32.5 ± 1.7 0.009 24.7 ± 1.1 33.0 ± 2.0 0.002
Whole-body fat (%) 24 ± 3 36 ± 1 0.009 28 ± 2 36 ± 1 0.002
Fat mass (kg) 15 ± 2 33 ± 3 0.009 20 ± 2 35 ± 4 0.003
Waist-to-hip ratio 0.86 ± 0.02 0.93 ± 0.02 0.047 0.86 ± 0.01 0.91 ± 0.01 0.03
fP-glucose (mmol/l) 5.0 ± 0.1 5.7 ± 0.2 0.016 5.1 ± 0.1 5.6 ± 0.2 0.012
fS-insulin (mU/l) 3 ± 0.5 11 ± 2 0.009 3 ± 0.4 10 ± 1 < 0.001
fS-LDL cholesterol (mmol/l) 2.2 ± 0.2 3.1 ± 0.2 0.016 2.2 ± 0.2 3.1 ± 0.2 0.004
fS-triglycerides (mmol/l) 0.9 ± 0.2 1.3 ± 0.2 0.076 0.78 ± 0.1 1.4 ± 0.2 0.002
fS-HDL cholesterol (mmol/l) 1.9 ± 0.09 1.4 ± 0.05 0.009 1.8 ± 0.08 1.4 ± 0.09 0.003
fS-C-peptide (nmol/l) 0.4 ± 0.03 0.8 ± 0.01 0.009 0.4 ± 0.03 0.8 ± 0.08 0.002
Data are mean ± SEM, fP = fasting plasma, fS = fasting serum
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sion of the oxidation reduction (GO:0055114) and cellular
alcohol metabolic (GO:0006066) pathways was detected in
the insulin-resistant group (Table 4).
Defective mRNA expression of nuclear mitochondrial
genes in insulin-resistant women during hyperinsulinemia
Reduced mRNA expression of mitochondrial pathways
was a predominant phenotype in the insulin-resistant
group during hyperinsulinemia (Table 5). Especially
genes in the mitochondrial respiratory chain (GO:
0005746, p = 9.7E-06) pathway were expressed at mark-
edly reduced levels in the insulin-resistant group as
compared with the insulin-sensitive group. The genes
were mostly those involved in mitochondrial complex I
function (Figure 3). In addition to genes encoding mito-
chondrial complexes I, III, and IV, the differentially
expressed genes in this pathway included fatty acid
desaturase 1 (FADS1) and peroxisome proliferator-acti-
vated receptor gamma, coactivator 1 alpha (PPARGC1)
transcribed at reduced levels in the insulin-resistant
women.
Induction of lipid metabolism pathways by insulin in the
two study groups
We next investigated the pathways most prominently
induced by insulin (Tables 6 &7). The ten most up-
regulated pathways were predominantly those involved
in lipid metabolism, in both the insulin-resistant and the
insulin-sensitive groups. More detailed analysis revealed
Table 2 Ten most up-regulated pathways in insulin-resistant compared to insulin-sensitive group after an overnight
fast
GO category Pathway name Nominal p Permuted p
GO:0006954 inflammatory response 2.0E-10 0.0001
GO:0007626 locomotory behavior 2.8E-09 0.0001
GO:0007610 behavior 4.5E-09 0.0001
GO:0002682 regulation of immune system process 4.1E-08 0.0001
GO:0050778 positive regulation of immune response 1.0E-07 0.0001
GO:0055080 cation homeostasis 1.4E-07 0.0001
GO:0002253 activation of immune response 1.5E-07 0.0001
GO:0006968 cellular defense response 1.6E-07 0.0001
GO:0042330 taxis/chemotaxis 1.8E-07 0.0001
GO:0002684 positive regulation of immune system process 2.3E-07 0.0001
Figure 1 Inflammatory response and chemotaxis pathways were up-regulated in insulin-resistant subjects. The x-axis shows the fold
change of gene expression in the inflammatory response (GO:0006954) (A) and chemotaxis pathways (GO:0006935) (B) under fasting conditions
in the insulin-resistant compared to the insulin-sensitive subjects. Genes encoding complement components are indicated.
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metabolic process (GO:0016125) pathways, despite that
fact that they were induced by insulin in both groups,
were expressed at lower levels in the insulin-resistant as
compared with the insulin-sensitive group during hyper-
insulinemia (Figure 4A &4B). Fatty acid binding protein
2( FATP2 or SLC27A2), fatty acid elongation factor 6
(ELOVL6), and patatin-like phospholipase domain con-
taining 3 (PNPLA3) were among the most divergently
expressed genes in the GO:0006629 pathway. The sterol
metabolic process pathway contained several genes with
well established roles in cholesterol metabolism, includ-
ing 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
(HMGCR) and sterol regulatory element binding tran-
scription factor 1 (SREBF1) (Figure 4B).
ANOVA analysis of single insulin-regulated genes
revealed a number of additional interesting lipid meta-
bolism-related transcripts whose levels differed between
the insulin-sensitive and -resistant groups (Additional
file 4: Table S3
Q4). One of these, angiopoietin-like pro-
tein 4 (ANGPTL4 or FIAF), is currently recognized as
an important regulator of lipoprotein lipase function,
the expression of which is strongly induced in mouse
adipose tissue during fasting [23]. This transcript was
elevated during hyperinsulinemia in the insulin-resistant
as compared to the insulin-sensitive group.
Quantitative RT-PCR analysis of mRNA levels of selected
genes altered by insulin or insulin resistance status
To verify some of the most interesting findings of the
microarray study, we performed qPCR quantification of
mRNAs for 8 genes, for 11 insulin-sensitive and 9 insulin-
resistant women, under fasting and at the 3 h and 6 h
time points of hyperinsulinemia. In all cases, the microar-
ray findings were confirmed. FATP2 mRNA remained at
lower levels in the insulin-resistant group during fasting
(p < 0.01) and the levels were not affected by hyperinsuli-
nemia in either group (Figure 5A). ELOVL6 was strongly
induced by insulin only in the insulin-sensitive group (p <
0.001) resulting in strikingly decreased mRNA levels in the
insulin-resistant compared to insulin-sensitive group (p <
0.01) at the 6 hour time point (Figure 5B). ANGPTL4 was
strongly down-regulated by insulin in the insulin-sensitive
g r o u p( p=<0 . 0 0 1 )w h e r e a st h i sr e g u l a t i o nw a sa l m o s t
Table 3 Ten most up-regulated pathways in insulin-resistant compared to insulin-sensitive group during euglycemic
hyperinsulinemic conditions
GO category Pathway name Nominal p Permuted p
GO:0032787 monocarboxylic acid metabolic process 5.6E-06 0.0001
GO:0055114 oxidation reduction 9.7E-06 0.0003
GO:0006066 cellular alcohol metabolic process 1.4E-05 0.0005
GO:0008131 amine oxidase activity 2.6E-05 0.0002
GO:0006631 fatty acid metabolic process 5.8E-05 0.0012
GO:0016638 oxidoreductase activity, acting on the CH-NH2 group of donors 1.0E-04 0.0003
GO:0006725 cellular aromatic compound metabolic process 1.2E-04 0.0022
GO:0006642 triacylglycerol mobilization 1.5E-04 0.0001
GO:0042594 response to starvation 2.1E-04 0.0012
GO:0016645 oxidoreductase activity, acting on the CH-NH group of donors 2.5E-04 0.002
Table 4 Ten most down-regulated pathways in insulin-resistant compared to insulin-sensitive group after an overnight
fast
GO category Pathway name Nominal p Permuted p
GO:0001934 positive regulation of protein amino acid phosphorylation 6.70E-08 0.0001
GO:0000904 cell morphogenesis during differentiation 1.62E-07 0.0001
GO:0048675 axon extension 2.63E-07 0.0001
GO:0006954 inflammatory response 3.71E-07 0.0001
GO:0005764 lysosome 6.78E-07 0.0001
GO:0010562 positive regulation of phosphorus metabolic process 7.14E-07 0.0001
GO:0005773 vacuole 7.18E-07 0.0001
GO:0002682 regulation of immune system process 1.02E-06 0.0001
GO:0006955 immune response 1.6E-07 0.0001
GO:0001932 regulation of protein amino acid phosphorylation 1.8E-07 0.0001
Soronen et al. BMC Medical Genomics 2012, 5:9
http://www.biomedcentral.com/1755-8794/5/9
Page 6 of 13absent in the insulin-resistant group (p = NS). As a conse-
quence we observed higher ANGPTL4 expression in the
insulin-resistant compared to the insulin-sensitive group
after 6 hours of hyperinsulinemia (Figure 5C). Further-
more, significantly higher mRNA levels of ANGPTL4 in
the insulin-sensitive group were observed during fasting in
analysis of the 5 most insulin-resistant and 5 most insulin-
sensitive persons analyzed in the microarray experiment
(p < 0.05, data not shown). PNPLA3 expression was lower
in the insulin-resistant compared to the insulin-sensitive
group during hyperinsulinemia (p < 0.001 at 3 h and p <
0.001 at 6 h) and the expression was increased by insulin
in both groups at 6 h time point and in the insulin-sensi-
tive group already at 3 h time point (p < 0.001) (Figure
5D). Expression of SREBF1 and its target HMGCR dis-
played significantly lower mRNA levels in the insulin-
resistant group after 3 h (p < 0.05 and p < 0.001) and 6 h
(p < 0.05 for both genes) of hyperinsulinemia (Figure 5E
&5F). The expression of both SREBF1 (p < 0.001 at 6 h for
insulin-sensitive, p < 0.01 for insulin-resistant) and
HMGCR (p < 0.001 at 6 h for the insulin-sensitive, p <
0.05 for the insulin-resistant) in both study groups was
up-regulated by insulin, although the activation was clearly
weaker in the insulin-resistant group. Expression of three
nuclear mitochondrial genes, NDUFS4, UQCR and
COX4I2, was verified by RT-PCR (Additional file 5). All
have lower expression in insulin-resistant as compared to
insulin-sensitive subjects, consistently at every time point
(p < 0.05).
Discussion
In the present study we compared the acute in vivo
effects of insulin on adipose tissue transcriptional pro-
files of obese insulin-resistant and lean insulin-sensitive
women, to gain insight into the molecular mechanisms
underlying insulin resistance. The most striking differ-
ence in gene expression of the insulin-resistant group
during hyperinsulinemia was reduced transcription of
genes involved in mitochondrial respiration (mitochon-
drial respiratory chain, GO:0001934). Inflammatory
pathways with complement components (inflammatory
response, GO:0006954) and cytokines (chemotaxis,
GO:0042330) were strongly up-regulated in insulin-
resistant as compared to insulin-sensitive subjects both
before and during hyperinsulinemia. Furthermore, differ-
ences were observed in genes contributing to fatty acid,
cholesterol and triglyceride metabolism and in genes
involved in regulating lipolysis, between the insulin-
resistant and -sensitive subjects especially during
hyperinsulinemia.
Low-grade adipose tissue inflammation has been pos-
tulated as one of the central factors in the development
of insulin resistance. Increased inflammation was a pre-
dominant phenotype in the insulin-resistant vs. insulin-
sensitive subjects in the present study. Many findings of
the up-regulated genes in the insulin-resistant group,
such as C1Q peptides, MMP9 and SPP1, are consistent
with previous reports on adipose tissue gene expression
Figure 2 Monocarboxylic acid metabolic process pathway was
down-regulated in insulin-resistant subjects. The x-axis shows
the fold change of gene expression in the monocarboxylic acid
metabolic process pathway (GO:0032787) under fasting conditions
in the insulin-resistant compared to the insulin-sensitive subjects.
Table 5 Ten most down-regulated pathways in insulin-resistant compared to insulin-sensitive group during
euglycemic hyperinsulinemic conditions
GO category Pathway name Nominal p Permuted p
GO:0005746 mitochondrial respiratory chain 9.7E-06 0.0002
GO:0044429 mitochondrial part 1.3E-05 0.001
GO:0022900 electron transport chain 1.6E-05 0.0002
GO:0050890 cognition 2.6E-05 0.0005
GO:0016651 oxidoreductase activity, acting on NADH or NADPH 3.9E-05 0.0002
GO:0005759 mitochondrial matrix 4.9E-05 0.0008
GO:0031349 positive regulation of defense response 7.3E-05 0.0008
GO:0022891 substrate-specific transmembrane transporter activity 8.9E-05 0.0022
GO:0003954 NADH dehydrogenase activity 1.0E-04 0.0023
GO:0055114 oxidation reduction 1.1E-04 0.0037
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obese mice [24,25], and in monozygotic twins discordant
for BMI [12]. While these data characterize changes in
adipose tissue transcriptome in humans and are unique
as such, the role of complement components and
inflammatory mediators in the development of insulin
resistance cannot be determined in a cross-sectional
study in humans. Since many of the inflammatory genes
observed in this study are active in cells of the mono-
cyte/macrophage lineage, our observation may reflect
increased inflammatory cell content in adipose tissue of
the insulin-resistant women. This is in line with the
observation that the adipose tissue of lean subjects
usually consists of approximately 5-10% of macrophages,
whereas in obese patients, adipose tissue macrophage
content can be as high as 50% of the total cell number
[26]. However, there is increasing evidence that some of
the genes we found up-regulated are expressed also by
adipocytes, such as complement components, PLA2G7
[27,28], SYK [29] and ITGB2[28]. Adipocyte and
macrophage trancriptomes are similar and they can
become even more similar after macrophages engulf
lipids [15] from the dying adipocytes observed in obesity
[30].
Alterations in fatty acid handling and release charac-
terize adipose tissue in obesity. In the present study one
of the most notable changes in adipose tissue transcrip-
tome of the insulin-resistant women during fasting was
down-regulation of the monocarboxylic acid metabolism
pathway, FATP2 being the most down-regulated gene in
this pathway. There are no previous reports describing
FATP2 expression in human adipose tissue. Moreover,
FATP2 is not expressed in mouse 3T3-L1 adipocytes
[31] and in murine tissues it is expressed most strongly
in liver and kidney cortex (data on adipose tissue not
available in this study) [32]. It seems unlikely that the
FATP2 signal in our study would originate from macro-
phages, since its transcription is strongly down-regulated
in the obese insulin-resistant group where macrophage
numbers are elevated [26]. Interestingly, a recent report
in rat peripheral blood mononuclear cells suggested
FATP2 to be an early marker of obesity [33].
ELOVL6 is a fatty acid elongation factor specific for
long chain fatty acids [34]. It which was recently shown
to be regulated by SREBP1c [35]. In the present study
we made a novel observation of ELOVL6 down-regula-
tion in the obese insulin resistant as compared to the
lean insulin-sensitive group in hyperinsulinemia. Inter-
estingly, liver deficiency of ELOVL6 significantly amelio-
rates insulin resistance in mice by modifying hepatic
fatty acid composition [36]. PNPLA3 is expressed mainly
in liver and adipose tissue and its genetic variants
associate in multiple studies with increased hepatic fat.
PNPLA3 has been shown to have a lipolytic and weak
lipogenic effect in vivo but its precise role in vivo is
unclear [37]. Its expression in adipose tissue has been
reported to be similar [38,39] or increased [40] in obese
compared to lean patients at fasting state. Both insulin
and glucose stimulate adipose tissue PNPLA3 expression
[39]. The dramatically lower transcript levels of ELOVL6
as well as PNPLA3 in hyperinsulinemic insulin-resistant
subjects might have an impact to adipocyte lipid compo-
sition and could further decline adipose tissue function
in insulin resistance.
Mitochondrial pathways, especially genes involved in
mitochondrial respiration, have been shown to be down-
regulated in muscle and adipose tissues of insulin-resis-
tant and type 2 diabetic subjects in fasting state [41,42].
Acquired obesity and poor physical fitness are known to
impair the expression of genes of oxidative phosphoryla-
tion (41). However, their response to insulin in insulin
resistant subjects has not been reported before. Mootha
et al. (41) presented evidence that a number of genes
involved in oxidative phosphorylation in skeletal muscle
Figure 3 Mitochondrial respiratory chain pathway was down-
regulated in insulin-resistant subjects. The x-axis shows the fold
change of gene expression in the mitochondrial respiratory chain
pathway (GO: 0005746) under hyperinsulinemic conditions in the
insulin-resistant compared to the insulin-sensitive subjects. Genes
encoding mitochondrial complexes I, III and IV are indicated.








GO:0016125 sterol metabolic process 1.52E-08 0.0001
GO:0006629 lipid metabolic process 2.31E-08 0.0001
GO:0008203 cholesterol metabolic process 1.12E-07 0.0001
GO:0044255 cellular lipid metabolic
process
1.36E-07 0.0001
GO:0008202 steroid metabolic process 6.34E-07 0.0001
GO:0016126 sterol biosynthetic process 4.45E-06 0.0002
GO:0006694 steroid biosynthetic process 4.93E-06 0.0001
GO:0001889 liver development 6.62E-06 0.0002
GO:0008015 blood circulation 1.00E-05 0.0002
GO:0042127 regulation of cell proliferation 1.77E-05 0.0006
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Page 8 of 13are subject to regulation by PGC-1a encoded by
PPARGC1, and are down-regulated in type 2 diabetes.
Therefore, the down-regulation of PPARGC1 we
observed in the subcutaneous fat of insulin resistant
subjects may provide one mechanistic explanation to the
reduced expression of mitochondrial respiratory chain
genes. Interestingly, decreased expression of mitochon-
drial pathways is the most prominent finding during
hyperinsulinemia reflecting a regulatory defect that may
further aggravate the pathogenesis of insulin resistance.
Since regular practice of physical exercise is known to
improve insulin sensitivity and reduce body weight
[43,44], it is possible that differences in physical activity
could have amplified the observed differences in gene
expression between the insulin sensitive and insulin
resistant subjects.
Activity of lipoprotein lipase (LPL) is an important
determinant in the development of obesity in mouse
models. As a general rule, high fat diet-induced adipo-
genesis is aggravated by stimulated LPL activity (e.g. by
adipose tissue-specifico v e re x p r e s s i o no fLPL or defi-
ciency for APOCIII), and attenuated by inhibited LPL
activity [45]. A physiologically important LPL inhibitor,
ANGPTL4, is strongly down-regulated by insulin in
mouse 3T3-L1 cells [46]. In the present study we found
insulin to significantly decrease ANGPTL4 expression in
human adipose tissue. This finding is novel as was the
finding of impaired acute insulin regulation of
ANGPTL4 in obese insulin resistant as compared to
lean insulin sensitive subjects. In mice, ANGPTL4 over
expression inhibits LPL, which in turn slows down adi-
pogenesis and increases plasma triglyceride concentra-
tions. When ANGPTL4 is deleted the reverse phenotype
arises [23,45,47]. Interestingly, serum ANGPTL4 levels
are inversely correlated with plasma glucose concentra-
tions and the serum levels are significantly lower in type
2 diabetic patients than healthy subjects [48]. ANGPTL4
expression is also stimulated by insulin sensitizing drugs
thiazolidinediones via PPARy mediated mechanism sug-
gesting that changes in ANGPTL level could have a role
in the development of insulin-resistance [49].
The insulin-resistant group displayed defective induc-
tion of important insulin-induced lipid metabolism path-
ways. While several genes in these pathways are
important players in cholesterol metabolism and have a
well established role in cholesterol synthesis in liver, lit-
tle is known of their importance in adipose tissue. Adi-
pose tissue contains the body’s largest pool of free
cholesterol and cholesterol imbalance is recognized as a
characteristic of enlarged adipocytes in obesity [50].
Therefore, the differentially expressed genes in the sterol
metabolic pathway in our data could play an important
part in the insulin-resistant phenotype. The molecular
Table 7 Ten most up-regulated pathways by insulin in the insulin-sensitive group
GO category Pathway name Nominal p Permuted p
GO:0048534/GO:0002520 hemopoietic or lymphoid organ development/immune system development 1.43E-05 0.0004
GO:0016125 sterol metabolic process 1.94E-05 0.0005
GO:0006469 negative regulation of protein kinase activity 2.86E-05 0.0002
GO:0009725 response to hormone stimulus 3.06E-05 0.001
GO:0030684 Preribosome 3.95E-05 0.0002
GO:0051348 negative regulation of transferase activity 4.78E-05 0.0003
GO:0006629 lipid metabolic process 5.94E-05 0.0023
GO:0008203 cholesterol metabolic process 6.44E-05 0.001
GO:0009887 organ morphogenesis 7.59E-05 0.0029
GO:0030097 hemopoiesis 7.68E-05 0.0023
Figure 4 Lipid and sterol metabolic process pathways were
down-regulated in insulin-resistant subjects. The x-axis shows
the fold change of gene expression in the lipid metabolic process
(GO:0006629) (A) and sterol metabolic process (GO:0016125) (B)
pathways under hyperinsulinemic conditions in the insulin-resistant
compared to the insulin-sensitive subjects.
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Page 9 of 13mechanism underlying the decreased expression of lipid
biosynthesis pathways in thei n s u l i n - r e s i s t a n tg r o u p
could involve SREBP-1c since several of the genes
shown in Figure 4 are targets of SREBP-1c including
HMGCR and ELOVL6 [35,51]. SREBP-1c is regulated
mainly at the transcriptional level and is a major media-
tor of fatty acid and triglyceride synthesis induction by
insulin in liver and adipose tissue [51-54]. Down-regula-
tion of SREBP-1c was observed in the adipose tissue of
leptin deficient mice (ob/ob) [55], in insulin-resistant
humans during fasting and in response to insulin [56],
and in adipose tissue of patients with type 2 diabetes
[57], similar to our study. In contrast to the latter study,
we detected no difference in SREBF1 expression
between the groups in the basal state. The small sample
size of the study could have contributed to failure to
detect such a difference and also other small scale
changes in gene expression. The defective response of
SREBF1 to insulin in the insulin-resistant group could
explain down-regulation of ELOVL6 and HMGCR
m R N A si nt h i sg r o u p .R e d u c e dSREBF1 transcription
could be a homeostatic reaction of enlarged adipocytes
to prevent further lipid synthesis. On the other hand,
the reduced SREBF1 expression could also decrease
Figure 5 Relative mRNA levels of genes involved in lipid metabolism and inflammation. Expression levels were analyzed in the insulin-
resistant (black bars) and the insulin-sensitive subjects (white bars) at 0 h, 3 h, and 6 h during euglycemic hyperinsulinemia. *p < 0.05, **p <
0.01, ***p < 0.001 for change between insulin-resistant and insulin-sensitive groups at each time point; #p < 0.05, ##p < 0.01, ###p < 0.001 for
change in response to euglycemic hyperinsulinemia between time points at 0 h vs. 3 h and 0 h vs. 6 h.
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Page 10 of 13lipogenesis in smaller adipocytes and hinder adipocyte
differentiation via PPARG down-regulation, leading to
increased insulin resistance [58].
Conclusions
In conclusion, our data demonstrate that insulin-resis-
tant subjects have a marked decrease in the expression
of numerous genes involved in lipid and mitochondrial
metabolism in human adipose tissue. This study also
replicates previous findings of increased inflammation in
adipose tissue of insulin-resistant human subjects. Insu-
lin resistance is a complex phenotype characterized by
disturbances in the transcriptional networks controlling
immune response, lipid metabolism and mitochondrial
function. While this study uncovers several novel aber-
rations in the obese and insulin-resistant human sub-
jects’ a d i p o s et i s s u e ,t h eu l t i m a t et r i g g e ro ft h e
transcriptional changes leading to adipose tissue dys-
function and insulin resistance remains to be identified.
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